# A First in Human Study of the Safety, Tolerability and Pharmacokinetics of PRV-002 in Healthy Volunteers

> **NCT05033444** · PHASE1 · COMPLETED · sponsor: **Odyssey Group International, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Traumatic Brain Injury (TBI)

## Interventions

- **DRUG:** PRV-002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05033444
- **Lead sponsor:** Odyssey Group International, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-09
- **Primary completion:** 2022-10-01
- **Final completion:** 2024-09-13
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05033444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05033444, "A First in Human Study of the Safety, Tolerability and Pharmacokinetics of PRV-002 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05033444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*